BioMarin Pharmaceuticals BMRN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's investing cash flow?
- BioMarin Pharmaceuticals (BMRN) reported investing cash flow of $725.53M in Q1 2026.
- How has BioMarin Pharmaceuticals's investing cash flow changed year-over-year?
- BioMarin Pharmaceuticals's investing cash flow increased by 2669.3% year-over-year, from -$28.24M to $725.53M.
- What does investing cash flow mean?
- The total net cash spent on or generated from investments.
- How do you interpret investing cash flow?
- Negative net cash is typical for growing companies investing in R&D and infrastructure, while positive net cash may indicate divestment or maturity of the business cycle.
- How does investing cash flow compare across companies?
- Standard metric across all industries; biotech firms typically show negative net cash due to heavy investment in R&D and infrastructure.